Initial classic Hodgkin lymphoma and subsequent diffuse large B-cell lymphoma: separate entities with a continuum of BCL2 rearrangement
Pathology · 2024
DOI: 10.1016/j.pathol.2023.05.019 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pathology, 2024. Verfasst von Brandon T Gehris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, TX, USA.
- Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: zhu6@mdanderson.org.
Zitieren
APA
Gehris, B. T., Wang, W. J., Mai, B., Chen, L., Wang, W., & Hu, Z. (2024). Initial classic Hodgkin lymphoma and subsequent diffuse large B-cell lymphoma: separate entities with a continuum of BCL2 rearrangement. Pathology. https://doi.org/10.1016/j.pathol.2023.05.019
Vancouver
Gehris BT, Wang WJ, Mai B, Chen L, Wang W, Hu Z. Initial classic Hodgkin lymphoma and subsequent diffuse large B-cell lymphoma: separate entities with a continuum of BCL2 rearrangement. Pathology. 2024. doi:10.1016/j.pathol.2023.05.019
BibTeX
@article{Gehris2024,
author = {Gehris, Brandon T and Wang, Wei J and Mai, Brenda and Chen, Lei and Wang, Wei and Hu, Zhihong},
title = {Initial classic Hodgkin lymphoma and subsequent diffuse large B-cell lymphoma: separate entities with a continuum of BCL2 rearrangement},
journal = {Pathology},
year = {2024},
doi = {10.1016/j.pathol.2023.05.019}
}
EUVIMED